Acro Biomedical Faces Financial Turmoil Amid Revenue Drought and Growing Losses

Company Overview: Acro Biomedical Co., Ltd. (PINK: ACBM) is engaged in developing and marketing nutritional products, focusing on cordyceps products. The company has faced challenges in generating revenue, with no sales recorded in the recent quarters.

Financial Performance (Income Statement Highlights):

• Q3 2023 Net Loss: $1,589,490, or $(0.03) per share.
• Q3 2022 Net Loss: $4,011,322, or $(0.07) per share.
• Operating Expenses Q3 2023: $1,588,700, a decrease from Q3 2022 expenses of $4,010,823.
• Research and Development Expenses: $396,550 in Q3 2023, down from $2,520,000 in Q3 2022.
• Provision for Doubtful Accounts: $480,000 written off in Q3 2023.
• Total Operating Expenses (YTD 2023): $8,786,966, a decrease from $12,012,343 in YTD 2022.
• Balance Sheet Total Assets: $19,027 as of September 30, 2023, a significant drop from $687,486 at December 31, 2022.
• Current Liabilities: Increased to $258,640 from $201,116 at the end of 2022.
• Accumulated Deficit: Expanded to $(32,597,258) from $(23,807,925) since year-end 2022.

Positive Aspects:

• The operating expenses have decreased, showcasing improved cost control.
• Reduction in reliance on consultants with expenses trending downward.

Negative Aspects:

• Continuous losses with no revenue generated during the nine months ended September 30, 2023.
• Significant write-off of accounts receivable ($480,000), indicating potential cash flow issues.
• Minimal cash reserves ($3,271) raising concerns for continued operations.
• Stock traded on Expert Market, limiting capital raising options.

Going Concern Issues:

Acro Biomedical's financial reports emphasize substantial doubts regarding its ability to continue as a going concern, primarily due to a lack of revenue, ongoing losses, and minimal cash resources. The company is seeking to fund operations through sales and equity financing but lacks active orders and funding agreements.

Conclusion:

While Acro Biomedical Co., Ltd. has made strides in reducing its operating costs, the lack of revenue, ongoing losses, and cash constraints present significant challenges. Stakeholders should remain cautious before making investment decisions.